Gosset Ownership
Private
Therapeutic Areas
Stage
Phase 2
Preclinical
Phase 1
Phase 2
Phase 3
Approved
Modalities
Glaceum General Information
Glaceum has advanced its lead compound, vutiglabridin, into Phase 2 clinical trials for Parkinson’s disease. Other programs are in earlier stages targeting obesity and NASH. The company focuses on small molecules that improve mitochondrial function to address metabolic diseases.
Contact Information
Primary Industry
Biotech
Corporate Office
Suwon, Gyeonggi-do
South Korea
South Korea
Drug Pipeline
HSG4112
Phase 2Key Partnerships
No major pharmaceutical or biotech partnerships publicly disclosed . Investors include Life Asset Management , PeopleBio , Korea Development Bank , J Curve Investment , Ryukyung PSG Asset Management , among others .
Glaceum Funding
No funding data available
To view Glaceum's complete valuation and funding history, request access »